Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Natera, Inc.NTRA · Entity 2635 | PRESIDENT, CLINICALDIAGNOSTICS | October 01, 2026 | October 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Natera, Inc.
Report date October 01, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 106,914 |
Ending reported balance
After 2026-10-01 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-10-01 · Sale · Disposed 200 · Balance 109,714 F1: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $411.55 to $411.69 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 2 · 2026-10-01 · Sale · Disposed 954 · Balance 108,760 F1: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. F3: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $412.8350 to $413.3100 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 3 · 2026-10-01 · Sale · Disposed 1,846 · Balance 106,914 F1: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. F4: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $414.44 to $415.19 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024.
F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $411.55 to $411.69 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $412.8350 to $413.3100 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $414.44 to $415.19 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2026 Filed Oct 3, 2026 01:35 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 1,846 | $415.07 | $766,217.56 |
DisclosureSEC source: 0002010019-26-000030 · form4-10022026_091001.xml · nonDerivative · entry 3 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 106,914 F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $414.44 to $415.19 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 01, 2026 Filed Oct 3, 2026 01:35 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 954 | $413.11 | $394,103.70 |
DisclosureSEC source: 0002010019-26-000030 · form4-10022026_091001.xml · nonDerivative · entry 2 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 108,760 F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $412.8350 to $413.3100 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 01, 2026 Filed Oct 3, 2026 01:35 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 200 | $411.62 | $82,324.00 |
DisclosureSEC source: 0002010019-26-000030 · form4-10022026_091001.xml · nonDerivative · entry 1 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 109,714 F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $411.55 to $411.69 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 02, 2026 Filed Sep 4, 2026 01:35 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 15,160 | $326.89 | $4,955,713.04 |
DisclosureSEC source: 0002010019-26-000028 · form4-09032026_090901.xml · nonDerivative · entry 4 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 110,859 F5 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and was made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on August 25, 2023. Read SEC document |
| September 01, 2026 Filed Sep 4, 2026 01:35 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 600 | $321.91 | $193,144.02 |
DisclosureSEC source: 0002010019-26-000028 · form4-09032026_090901.xml · nonDerivative · entry 3 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 126,019 F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $321.49 to $322.11 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 01, 2026 Filed Sep 4, 2026 01:35 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 1,400 | $320.92 | $449,291.50 |
DisclosureSEC source: 0002010019-26-000028 · form4-09032026_090901.xml · nonDerivative · entry 2 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 126,619 F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $320.36 to $321.17 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 01, 2026 Filed Sep 4, 2026 01:35 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 1,000 | $319.76 | $319,758.20 |
DisclosureSEC source: 0002010019-26-000028 · form4-09032026_090901.xml · nonDerivative · entry 1 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 128,019 F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $319.2850 to $320.26 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 03, 2026 Filed Aug 6, 2026 01:35 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 128 | $268.70 | $34,393.14 |
DisclosureSEC source: 0002010019-26-000024 · form4-08052026_090806.xml · nonDerivative · entry 7 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 129,019 F2 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. F7 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $268.63 to $268.73 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 03, 2026 Filed Aug 6, 2026 01:35 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 1,233 | $267.79 | $330,181.25 |
DisclosureSEC source: 0002010019-26-000024 · form4-08052026_090806.xml · nonDerivative · entry 6 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 129,147 F2 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. F6 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $267.1550 to $268.1150 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 03, 2026 Filed Aug 6, 2026 01:35 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 192 | $265.28 | $50,932.80 |
DisclosureSEC source: 0002010019-26-000024 · form4-08052026_090806.xml · nonDerivative · entry 5 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 130,380 F2 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. F5 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $265.27 to $265.28 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 03, 2026 Filed Aug 6, 2026 01:35 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 947 | $263.94 | $249,952.60 |
DisclosureSEC source: 0002010019-26-000024 · form4-08052026_090806.xml · nonDerivative · entry 4 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 130,572 F2 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $263.6550 to $264.2400 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 03, 2026 Filed Aug 6, 2026 01:35 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 200 | $261.49 | $52,297.50 |
DisclosureSEC source: 0002010019-26-000024 · form4-08052026_090806.xml · nonDerivative · entry 3 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 131,519 F2 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $261.1500 to $261.8250 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 03, 2026 Filed Aug 6, 2026 01:35 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 300 | $259.98 | $77,994.00 |
DisclosureSEC source: 0002010019-26-000024 · form4-08052026_090806.xml · nonDerivative · entry 2 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 131,719 F2 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. Read SEC document |
| August 03, 2026 Filed Aug 6, 2026 01:35 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 410 | $267.99 | $109,875.61 |
DisclosureSEC source: 0002010019-26-000024 · form4-08052026_090806.xml · nonDerivative · entry 1 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 132,019 F1 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and was made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 31, 2025. Read SEC document |
| July 28, 2026 Filed Jul 30, 2026 01:35 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 1,204 | $254.07 | $305,900.88 |
DisclosureSEC source: 0002010019-26-000021 · form4-07292026_090707.xml · nonDerivative · entry 2 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 132,429 F2 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and was made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 27, 2023. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $254.0696 to $254.3500 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 27, 2026 Filed Jul 30, 2026 01:35 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 1,010 | $260.49 | $263,095.71 |
DisclosureSEC source: 0002010019-26-000021 · form4-07292026_090707.xml · nonDerivative · entry 1 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 133,633 F1 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of Restricted Stock Units ("RSUs") and was made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 26, 2024. Read SEC document |
| July 01, 2026 Filed Jul 7, 2026 01:05 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 300 | $274.06 | $82,218.00 |
DisclosureSEC source: 0002010019-26-000016 · form4-07062026_090701.xml · nonDerivative · entry 3 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 134,643 F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. Read SEC document |
| July 01, 2026 Filed Jul 7, 2026 01:05 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 2,600 | $272.99 | $709,774.00 |
DisclosureSEC source: 0002010019-26-000016 · form4-07062026_090701.xml · nonDerivative · entry 2 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 134,943 F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $272.74 to $273.00 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 01, 2026 Filed Jul 7, 2026 01:05 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 100 | $267.19 | $26,718.50 |
DisclosureSEC source: 0002010019-26-000016 · form4-07062026_090701.xml · nonDerivative · entry 1 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 137,543 F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $267.05 to $267.30 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 01, 2026 Filed Jun 4, 2026 01:05 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 572 | $220.67 | $126,221.75 |
DisclosureSEC source: 0002010019-26-000015 · form4-06032026_090604.xml · nonDerivative · entry 4 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 137,643 F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $220.52 to $220.83 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 01, 2026 Filed Jun 4, 2026 01:05 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 213 | $219.34 | $46,719.42 |
DisclosureSEC source: 0002010019-26-000015 · form4-06032026_090604.xml · nonDerivative · entry 3 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 138,215 F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. Read SEC document |
| June 01, 2026 Filed Jun 4, 2026 01:05 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 413 | $218.84 | $90,382.78 |
DisclosureSEC source: 0002010019-26-000015 · form4-06032026_090604.xml · nonDerivative · entry 2 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 138,428 F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $218.2250 to $219.0900 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 01, 2026 Filed Jun 4, 2026 01:05 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 1,802 | $217.52 | $391,970.86 |
DisclosureSEC source: 0002010019-26-000015 · form4-06032026_090604.xml · nonDerivative · entry 1 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 138,841 F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $217.01 to $218.00 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 26, 2026 Filed May 29, 2026 01:05 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 1,652 | $202.84 | $335,091.35 |
DisclosureSEC source: 0002010019-26-000014 · form4-05282026_090503.xml · nonDerivative · entry 1 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 140,643 F1 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on June 10, 2022. Read SEC document |
| May 01, 2026 Filed May 6, 2026 01:35 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 150 | $206.93 | $31,039.50 |
DisclosureSEC source: 0002010019-26-000013 · form4-05052026_090506.xml · nonDerivative · entry 7 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 142,295 F2 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. Read SEC document |
| May 01, 2026 Filed May 6, 2026 01:35 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 400 | $205.31 | $82,123.00 |
DisclosureSEC source: 0002010019-26-000013 · form4-05052026_090506.xml · nonDerivative · entry 6 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 142,445 F2 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. F7 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $205.19 to $205.56 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 01, 2026 Filed May 6, 2026 01:35 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 865 | $204.47 | $176,862.83 |
DisclosureSEC source: 0002010019-26-000013 · form4-05052026_090506.xml · nonDerivative · entry 5 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 142,845 F2 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. F6 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $204.17 to $205.05 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 01, 2026 Filed May 6, 2026 01:35 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 505 | $203.32 | $102,674.33 |
DisclosureSEC source: 0002010019-26-000013 · form4-05052026_090506.xml · nonDerivative · entry 4 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 143,710 F2 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. F5 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $203.00 to $203.81 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 01, 2026 Filed May 6, 2026 01:35 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 520 | $201.60 | $104,832.21 |
DisclosureSEC source: 0002010019-26-000013 · form4-05052026_090506.xml · nonDerivative · entry 3 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 144,215 F2 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $201.5200 to $20.6150 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 01, 2026 Filed May 6, 2026 01:35 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 560 | $200.95 | $112,533.29 |
DisclosureSEC source: 0002010019-26-000013 · form4-05052026_090506.xml · nonDerivative · entry 2 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 144,735 F2 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $200.31 to $201.23 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 01, 2026 Filed May 6, 2026 01:35 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 405 | $206.16 | $83,494.80 |
DisclosureSEC source: 0002010019-26-000013 · form4-05052026_090506.xml · nonDerivative · entry 1 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 145,295 F1 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and was made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 31, 2025. Read SEC document |
| April 27, 2026 Filed Apr 30, 2026 01:35 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 1,185 | $204.39 | $242,202.15 |
DisclosureSEC source: 0002010019-26-000012 · form4-04292026_090406.xml · nonDerivative · entry 2 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 145,700 F2 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and was made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 27, 2023. Read SEC document |
| April 27, 2026 Filed Apr 30, 2026 01:35 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 997 | $203.75 | $203,138.75 |
DisclosureSEC source: 0002010019-26-000012 · form4-04292026_090406.xml · nonDerivative · entry 1 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 146,885 F1 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of Restricted Stock Units ("RSUs") and was made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 26, 2024. Read SEC document |
| April 01, 2026 Filed Apr 4, 2026 01:05 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 952 | $203.31 | $193,551.69 |
DisclosureSEC source: 0002010019-26-000011 · form4-04032026_090401.xml · nonDerivative · entry 3 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 147,882 F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $203.08 to $203.51 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 01, 2026 Filed Apr 4, 2026 01:05 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 1,000 | $202.36 | $202,363.80 |
DisclosureSEC source: 0002010019-26-000011 · form4-04032026_090401.xml · nonDerivative · entry 2 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 148,834 F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $202.0800 to $202.6150 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 01, 2026 Filed Apr 4, 2026 01:05 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 1,048 | $201.32 | $210,983.99 |
DisclosureSEC source: 0002010019-26-000011 · form4-04032026_090401.xml · nonDerivative · entry 1 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 149,834 F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $201.00 to $201.93 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 10, 2026 Filed Mar 11, 2026 22:05 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 915 | $204.13 | $186,781.42 |
DisclosureSEC source: 0002010019-26-000008 · form4-03112026_060302.xml · nonDerivative · entry 2 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 150,882 F3 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and was made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on March 9, 2026. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 22:05 UTC | Natera, Inc. NTRA · Entity 2635 | GrantCommon Stock | 1,774 | Not disclosed | Not disclosed |
DisclosureSEC source: 0002010019-26-000008 · form4-03112026_060302.xml · nonDerivative · entry 1 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 151,797 F1 · shares: Represents the issuance of Restricted Stock Units ("RSUs") to the Reporting Person. The RSUs were fully-vested at the time of issuance. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 02:05 UTC | Natera, Inc. NTRA · Entity 2635 | Exercise / conversionStock Option (right to buy) · Derivative | 5,125 | $0.00 Strike: $9.59 | $0.00 |
DisclosureSEC source: 0002010019-26-000007 · form4-03032026_090301.xml · derivative · entry 6 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,125 shares Expires 2026-04-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option shares are fully exercisable. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 02:05 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 475 | $200.97 | $95,459.75 |
DisclosureSEC source: 0002010019-26-000007 · form4-03032026_090301.xml · nonDerivative · entry 5 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 150,023 F3 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. F6 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $200.72 to $201.16 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 02:05 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 1,594 | $200.11 | $318,971.04 |
DisclosureSEC source: 0002010019-26-000007 · form4-03032026_090301.xml · nonDerivative · entry 4 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 150,498 F3 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. F5 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $199.6750 to $200.5100 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 02:05 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 931 | $198.83 | $185,114.27 |
DisclosureSEC source: 0002010019-26-000007 · form4-03032026_090301.xml · nonDerivative · entry 3 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 152,092 F3 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $198.42 to $199.25 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 02:05 UTC | Natera, Inc. NTRA · Entity 2635 | Exercise / conversionCommon Stock | 5,125 | $9.59 | $49,148.75 |
DisclosureSEC source: 0002010019-26-000007 · form4-03032026_090301.xml · nonDerivative · entry 2 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 153,023 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 27, 2026 Filed Mar 4, 2026 02:05 UTC | Natera, Inc. NTRA · Entity 2635 | GrantCommon Stock | 10,051 | Not disclosed | Not disclosed |
DisclosureSEC source: 0002010019-26-000007 · form4-03032026_090301.xml · nonDerivative · entry 1 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 147,898 F1 · shares: Represents the issuance of Restricted Stock Units ("RSUs") to the Reporting Person. The RSUs vest over four years. 25% of the RSUs vest on March 1, 2027 and the remaining RSUs vest in 12 equal quarterly installments thereafter. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| February 03, 2026 Filed Feb 5, 2026 02:35 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 1,639 | $230.77 | $378,228.75 |
DisclosureSEC source: 0002010019-26-000006 · form4-02042026_090205.xml · nonDerivative · entry 7 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 137,847 F6 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 31, 2025. Read SEC document |
| February 02, 2026 Filed Feb 5, 2026 02:35 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 16 | $234.00 | $3,744.00 |
DisclosureSEC source: 0002010019-26-000006 · form4-02042026_090205.xml · nonDerivative · entry 6 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 139,486 F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. Read SEC document |
| February 02, 2026 Filed Feb 5, 2026 02:35 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 600 | $233.24 | $139,942.02 |
DisclosureSEC source: 0002010019-26-000006 · form4-02042026_090205.xml · nonDerivative · entry 5 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 139,502 F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. F5 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $232.94 to $233.82 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 02, 2026 Filed Feb 5, 2026 02:35 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 850 | $232.33 | $197,476.51 |
DisclosureSEC source: 0002010019-26-000006 · form4-02042026_090205.xml · nonDerivative · entry 4 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 140,102 F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $231.94 to $232.92 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 02, 2026 Filed Feb 5, 2026 02:35 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 576 | $230.84 | $132,963.78 |
DisclosureSEC source: 0002010019-26-000006 · form4-02042026_090205.xml · nonDerivative · entry 3 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 140,952 F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $230.6150 to $231.1400 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 02, 2026 Filed Feb 5, 2026 02:35 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 878 | $229.96 | $201,902.86 |
DisclosureSEC source: 0002010019-26-000006 · form4-02042026_090205.xml · nonDerivative · entry 2 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 141,528 F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $229.5700 to $230.5150 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.